Duchenne Muscular Dystrophy

Sarepta to seek speedy approval of third DMD drug
Biopharma Dive
Thu, 03/28/19 - 07:57 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
casimersen
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
Sat, 03/2/19 - 12:44 pm
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
CRISPR corrects DMD in mice for a year in Sarepta-supported study
Fierce Biotech
Mon, 02/18/19 - 11:29 am
Duke University
Sarepta Therapeutics
CRISPR
gene editing
DMD
Duchenne Muscular Dystrophy
Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD
Endpoints
Thu, 02/7/19 - 09:37 am
Solid Biosciences
clinical trials
Duchenne Muscular Dystrophy
SGT-001
Suvodirsen For Duchenne Muscular Dystrophy Selected for FDA Complex Innovative Trial Designs Pilot Program
CP Wire
Thu, 01/3/19 - 09:43 am
suvodirsen
Wave Life Sciences
Duchenne Muscular Dystrophy
muscular dystrophy
Suvodirsen For Duchenne Muscular Dystrophy Selected for FDA Complex Innovative Trial Designs Pilot Program
Thu, 01/3/19 - 09:41 am
suvodirsen
Wave Life Sciences
Duchenne Muscular Dystrophy
muscular dystrophy
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Increase collaboration to widen access to DMD drugs, trials and care
Pharmaforum
Wed, 10/31/18 - 09:57 am
Duchenne Muscular Dystrophy
clinical trials
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Forbes
Thu, 10/4/18 - 12:36 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
CP Wire
Tue, 09/25/18 - 11:41 am
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
Tue, 09/25/18 - 10:12 am
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
Endpoints
Mon, 09/24/18 - 09:59 am
Sarepta Therapeutics
FDA
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Fri, 09/21/18 - 09:49 am
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Researchers Use CRISPR to Treat Duchenne Muscular Dystrophy in Dogs
BioSpace
Sat, 09/1/18 - 03:41 pm
DMD
Duchenne Muscular Dystrophy
CRISPR
drug development
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
CP Wire
Thu, 08/30/18 - 10:14 am
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Thu, 08/30/18 - 09:31 am
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?
Xtalks
Fri, 08/3/18 - 09:44 am
Mallinckrodt
MNK-1411
Duchenne Muscular Dystrophy
clinical trials
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
Endpoints
Thu, 07/26/18 - 11:53 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
clinical hold
gene therapy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
CP Wire
Mon, 07/9/18 - 10:51 am
edasalonexent
clinical trials
Duchenne Muscular Dystrophy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Mon, 07/9/18 - 09:07 am
Catabasis
edasalonexent
Duchenne Muscular Dystrophy

Pages